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Abstract
Aims To examine the relationship between visual acuity in each eye and Quality of Life (QoL) outcomes in people with
diabetic macular oedema.
Methods Cross sectional retrospective analysis of data collected at baseline in 289 people entered into a randomized
clinical trial with diabetic macular oedema which investigated the safety and efficacy of a vascular endothelial growth
factor inhibitor, pegaptanib sodium. At the baseline visit, visual acuity was measured through refraction and using
retro-illuminated modified Early Treatment Diabetic Retinopathy Study Log MAR charts, and patient health-related
QoL was determined using the European Quality of Life EQ–5D–3L and the Visual Functioning Questionnaire–25
(NEI–VFQ25). A regression analysis with QoL score from each vision-related domain as the dependent variable was
fitted using linear and quadratic terms of the better and worse eye, age, gender, adjusted for number of concurrent
conditions, ethnicity and level of diabetes control.
Results For all vision-related QoL domains from NEI–VFQ25 and EQ–5D–3L except ocular pain, both visual
acuity in the better-seeing and the worse-seeing eye gave a significant increase in correlation coefficient over that
obtained from clinical and demographic data. The NEI–VFQ25 correlation was most closely associated with a
weighted visual acuity measure of 0.75 in the better and 0.25 in the worse eye or 0.60 in the better and 0.40 in the
worse eye.
Conclusions We recommend that a weighted visual acuity measure from both eyes is considered in future diabetic
macular oedema trials.
Diabet. Med. 32, 97–101 (2015)
Introduction
Diabetes is estimated to be increasing worldwide from
382 million in 2013 to 592 million in 2035 [1], and is a
major cause of morbidity worldwide [2], with the incidence
of diabetic retinopathy increasing in parallel. In people with
diabetic retinopathy, the major cause of moderate vision loss
is diabetic macular oedema, which can progress to cause
increased visual impairment and eventual blindness, as
defined by the World Health Authority definition of visual
acuity (VA) ≤ 6/60 (log MAR ≥ 1.00) in the better-seeing
eye [3].
The health-related quality of life (HRQoL) of people with
diabetic macular oedema is adversely affected at all stages of
the disease [4,5]. Our current analysis was designed to use the
baseline Quality of Life (QoL) EQ–5D–3L and NEI–VFQ 25
data and the VA data from a recent clinical trial [6] to
determine the impact of the level of vision in the better- and
worse-seeing eye on QoL, as a relative weighting between the
vision in the two eyes as had previously been suggested in
people with macular degeneration by Pleil et al. [7].
The EuropeanQuality of Life (EuroQol) Group EQ–5D–3L
[8] is a generic instrument for describing and valuing health. It
consists of two parts, the first having five domains fromwhich
the responses are combined using an algorithm to provide a
single index value usingMVHweights [9], for the health status
of the individual; a score of 1 corresponds to perfect health,
and a score of 0 corresponds to being dead. The second part of
the tool is a visual analogue scale.
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The second questionnaire was the National Eye Insti-
tute-Visual Functioning Questionnaire 25(NEI–VFQ 25)
[10]. It comprises 25 items to assess the difficulty of visual
symptoms or day-to-day activities with 11 vision-related
domains. All responses, apart from the general health
question, are combined to provide a single composite score.
Methods
This retrospective analysis used baseline data from partici-
pants enrolled in the multicentre, Phase 2/3, randomized,
sham-controlled, double-masked, 2-year, comparative trial
(NCT 00605280) [11] in ophthalmology treatment centres
in the USA, Canada, Australia, Europe, South America and
India. Participants were ≥ 18 years of age with Type 1 or
Type 2 diabetes and diabetic macular oedema involving the
centre of the macula not associated with ischaemia. Partic-
ipants were administered intravitreal injections of pegaptanib
sodium 0.3 mg or sham injection every 6 weeks for up to
2 years. Details of inclusion and exclusion criteria, trial
design and results can be obtained from the original
publication of this trial [11].
Patient HRQoL was determined using the two separate
instruments, the EQ–5D–3L and the NEI–VFQ 25
described above. Both instruments were administered to
participants between the screening and baseline visit. In
India, the two questionnaires were administered in the clinic
by trained study personnel using paper-based versions
which were faxed to the call centre for data entry onto
the system. In all other centres, the questionnaires were
administered in the participants’ local language by trained
interviewers at a call centre and data were entered directly
into a database.
In the trial, baseline VA was measured through refraction
and using retro-illuminated modified Early Treatment Dia-
betic Retinopathy Study (ETDRS) Log MAR charts. Distance
VA was expressed as an ETDRS score (number of letters
correctly read) ranging from 0 to 94, where higher ETDRS
scores represented better vision.
Linear regression models with QoL score from each
vision-related domain and with the EQ–5D index value as
the dependent variables were fitted using linear and qua-
dratic terms in the terms of the better and worse eye, age and
gender, and were adjusted for number of concurrent condi-
tions, ethnicity and level of diabetes control. Stepwise model
selection procedures were used. All analyses were carried out
using SAS v. 9.1.
Results
The countries of origin of the 326 participants were: USA
(50), Canada (7), Australia (5), South America (10), India
(27) and Europe (188), including Austria (9), Czech Republic
(69), Denmark (4), France (33), Germany (26), UK (7), Italy
(25), the Netherlands (3), Portugal (10) and Switzerland (2).
Of the 326 participants, 37 did not have a composite VFQ
result, i.e. they did not complete every section of the
VFQ 25, and hence results are available for 289 participants
in this trial with diabetic macular oedema, 55% were male
and 82% were Caucasian (see Table 1). The range of VA in
the better-seeing eye was 35–94 letters, median interquartile
(IQR) range 69 (62–77) letters. The range of VA in the
worse-seeing eye was 0–70, 56 (46–63) letters. The correla-
tion coefficient (r2) between VA in the better and worse eyes
was 0.57 (P < 0.0001).
The results of the regression analyses (Table 2) show that
the proportion of variance in QoL scores explained by age
group, gender, HbA1c group and ethnicity, although statis-
Table 1 Characteristics of the study population
N %
Gender Men 160 55.4
Women 129 44.6
Ethnicity Caucasian 237 82.0
Asian 28 9.7
Hispanic 13 4.5
Black 7 2.4
Other 4 1.4
Diabetes Type 1 26 9.0
Type 2 263 91.0
Smoker No 20 6.9
Yes 269 93.1
HbA1c < 60 mmol/mol
(< 7.6%)
135 46.7
≥ 60 mmol/
mol≥ 7.6%)
154 53.3
Body Mass Index
(weight (kg)/
(height (m)2)†
29.8 (5.5)
Systolic blood
pressure (mmHg)†
138 (14)
Diastolic blood
pressure (mmHg)†
78 (9)
Visual acuity
(ETDRS letters) in
better eye*
69 (61–77)
Visual acuity
(ETDRS letters) in
better eye†
69.1 (11.7)
Visual acuity
(ETDRS letters) in
worse eye*
56 (46–63)
Visual acuity
(ETDRS letters) in
worse eye†
52.4 (13.4)
Number illnesses
recorded*
4 (2–6)
*Median (25th to 75th centiles); †Mean (SD).
What’s new?
• This study is the first to highlight the importance of
using both eyes in assessing Quality of Life in diabetic
macular oedema using a weighting between the better-
and worse-seeing eyes.
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Table 2 Regression analyses relating Quality of Life scores to vision
Incremental r2 beyond age group, gender, HbA1c group, race
n
Mean
score SD
r2 for fitting
age group,
gender, HbA1c
group, race
VA better
eye
VA worse
eye
0.75 VA
better eye
+0.25 VA
worse eye
0.6 VA
better eye
+0.4 VA
worse eye
0.5 VA better
eye +0.5 VA
worse eye
General health 289 41.1 22.5 0.040 0.031 0.0027 0.019 0.0197 0.033 0.0018 0.032 0.0021 0.030 0.0027
General vision 289 54.3 17.8 0.017 0.137 < 0.0001 0.098 < 0.0001 0.152 < 0.0001 0.152 < 0.0001 0.148 < 0.0001
Ocular pain 289 78.8 22.9 0.061 0.002 0.4884 0.007 0.1469 0.003 0.3195 0.004 0.2479 0.005 0.2134
Near activities 289 57.9 23.7 0.029 0.158 < 0.0001 0.094 < 0.0001 0.169 < 0.0001 0.164 < 0.0001 0.157 < 0.0001
Distant activities 289 63.5 24.7 0.022 0.192 < 0.0001 0.109 < 0.0001 0.202 < 0.0001 0.195 < 0.0001 0.185 < 0.0001
Vision-specific
Social
functioning
289 79.3 23.2 0.052 0.128 < 0.0001 0.079 < 0.0001 0.138 < 0.0001 0.135 < 0.0001 0.129 < 0.0001
Mental health 289 55.9 28.3 0.089 0.098 < 0.0001 0.068 < 0.0001 0.109 < 0.0001 0.108 < 0.0001 0.105 < 0.0001
Role difficulties 289 54.4 28.3 0.059 0.080 < 0.0001 0.080 < 0.0001 0.097 < 0.0001 0.102 < 0.0001 0.102 < 0.0001
Dependency 289 68.4 31.3 0.109 0.094 < 0.0001 0.088 < 0.0001 0.113 < 0.0001 0.117 < 0.0001 0.117 < 0.0001
Driving 148 67.9 23.3 0.140 0.115 < 0.0001 0.070 0.0006 0.127 < 0.0001 0.127 < 0.0001 0.123 < 0.0001
Colour vision 287 86.2 21.9 0.024 0.022 0.0112 0.030 0.0032 0.030 0.0034 0.033 0.0021 0.034 0.0017
Peripheral vision 288 71.4 25.9 0.023 0.084 < 0.0001 0.095 < 0.0001 0.106 < 0.0001 0.114 < 0.0001 0.116 < 0.0001
Composite 289 66.2 19.2 0.060 0.160 < 0.0001 0.135 < 0.0001 0.186 < 0.0001 0.190 < 0.0001 0.188 < 0.0001
EQ5D 289 0.738 0.2 0.071 0.019 0.0160 0.033 0.0015 0.027 0.0038 0.032 0.0019 0.033 0.0014
Some items, e.g. driving have a response choice that indicates that the respondent does not perform the activity for reasons unrelated to vision. If a respondent selects this choice, the answer is
treated as missing and an average of the remaining items is calculated. This is the reason for the reduced number in some domains.
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tically significant, was not large (highest r2 = 0.14 for
driving).
Table 2 shows the relative contributions of the better- and
worse-seeing eyes to the QoL scores, alone and in combina-
tion of better seeing/worse seeing 0.75/0.25, then 0.60/0.40
and the last being 0.50/0.50. These combinations were
chosen with higher contributions in the better-seeing eye
because r2 values for the NEI–VFQ 25 in Table 2 show that
the contribution of the worse eye is less than that of the
better-seeing eye.
There was a relationship (P = 0.016) between EQ–5D–3L
scores and VA in the better-seeing eye, for those with a VA in
the better eye of < 60 letters, the median EQ–5D–3L score
was 0.73 (0.59–0.81), and for those with a VA of ≥ 80 in the
better-seeing eye, the median EQ–5D–3L score was 0.80
(0.69–0.94).
By using the QoL data, the current analysis did not
show a strong correlation (levels of 0.027–0.033) with the
EQ–5D–3L.
For the NEI–VFQ 25, there was no relationship between
VA in either eye and ocular pain. There was a stronger
correlation between visual loss and other QoL domains (e.g.
distance 0.185–0.202 and near 0.157–0.169) and composite
scores (0.186–0.19) using the NEI–VFQ 25. This links most
closely to the visual loss in the better-seeing eye, but there is
also a correlation with the worse-seeing eye. For all other
vision-related QoL domains the VA in both the better and
the worse eye gave a significant increase in r2. Different
combinations of VA in the better- and worse-seeing eyes
show different effects on the QoL scores. For all but colour
and peripheral vision, the increase was significantly larger for
VA in the better than the worse-seeing eye.
For the three combinations of VA in the better- and
worse-seeing eyes presented in Table 2, the incremental
increase in r2 was larger for combinations of VA in the
better- and worse-seeing eyes than for either eye alone.
The domains for which this was greatest were for the
composite scores of peripheral vision, role difficulties and
dependency.
Discussion
In 2002, Brown et al. [12] reported that visual loss caused a
diminution in self-assessed quality of life but did not appear
to be affected by the presence of co-morbidities. However,
Davidov et al. [4] found that, as well as ocular disease levels
of diabetic retinopathy, patient co-morbidities lead to
significant impairment of both the physical and mental
components of the HRQoL. A study of the impact of laser
treatment [13] concluded that, after a pronounced reduction
of quality-of-life impacts following the first laser treatment,
there was an increasing negative impact as people move from
first treatment to multiple treatments.
Previous studies [5,14] have demonstrated a correlation
between lower QoL scores using the NEI–VFQ 25 and loss
of vision in diabetic macular oedema and proliferative
diabetic retinopathy.
This study does have some limitations:
1. The insensitivity of the EQ–5D for visual disorders is well
established [15,16].
2. Furthermore, mapping NEI–VFQ 25 scores to EQ–5D
utilities has been shown to provide low predictive power,
suggesting an inability of the EQ–5D to discriminate
vision-related activities [17].
However, the EQ–5D is an important tool that is used to
determine cost-effectiveness for appraisals of new pathways
and treatments by the National Institute for Health and
Clinical Excellence (NICE) in England. We believe that, in
such appraisals, data from both eyes should be used.
A recent review [18] found a stronger correlation between
health state utility values (HSUVs) and better-seeing eye VA
compared with worse-seeing eye VA. Our study has demon-
strated that the VA in both eyes needs to be considered and is
the first study to report a correlation between VA in the
better- and worse-seeing eyes in diabetic macular oedema.
We would recommend that a weighted VA measure of
0.75 in the better and 0.25 in the worse eye, or 0.60 in the
better and 0.40 in the worse eye is used in future diabetic
macular oedema trials because this study has demonstrated
that the most information can be provided by taking into
account vision in both eyes when determining the effect on
quality of life.
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